UroGen Pharma Ltd. (URGN)

SEC filing

UroGen Pharma Ltd.

URGN · CIK 1668243

4 · Oct 9, 2026 · Chief Financial Officer Degnan Chris sold 2,202 shares at $36.69/share ($80,791); exercised options for 8,966 shares

Chief Financial Officer Degnan Chris sold 2,202 shares at $36.69/share ($80,791); exercised options for 8,966 shares

FORM 4

xslF345X06/rdgdoc.xmlSEC.gov

Graphics and non-inline formats (not embedded below).